Cite
HARVARD Citation
Mustea, A. et al. (n.d.). 2754 First interim analysis of OTILIA, a large German non-interventional study evaluating front-line bevacizumab (BEV)-containing therapy in patients with ovarian cancer (OC). European journal of cancer. pp. S548-. [Online].